

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: [HEMP FOR HEALTH INC.](#) (the “Issuer”).

Trading Symbol: [HFH](#)

Number of Outstanding Listed Securities: [24,162,001](#)

Date: [June 4, 2021](#)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

[See news releases dated May 18 and May 31, 2021.](#)

2. Provide a general overview and discussion of the activities of management.

[Further to its news releases dated February 4 and April 7, 2021, HEMP FOR HEALTH INC. \(“HFH”\) announced that the letter of intent whereby HFH was proposing to acquire 100% of the outstanding shares of Pacific Hemp Company Pty Ltd. \(“PHC”\) \(the “Transaction”\) has been terminated.](#)

“Unfortunately, PHC was unable to meet its minimum obligations and consequently, the Definitive Agreement, originally scheduled to be executed by March 31, 2021, was still not signed by the extended deadline date of May 17, 2021,” said Robert Eadie, President and CEO of HFH.

“The project with PHC is synergistic and has great merits. It would have been an excellent opportunity for our Company to grow and expand into the international market,” added Mr. Eadie. “However, due to a number of logistical challenges compounded by the COVID situation, the Transaction was taking much longer to complete than originally anticipated. Our shareholders are anxious for us to move forward and have us resume trading. Should the complications be resolved in a timely manner, we would be happy to revisit the situation,” concluded Mr. Eadie.

On May 31, 2021 the Company provided a corporate update for its shareholders.

As reported in our news release of May 18, 2021, the agreement to acquire 100% of Pacific Hemp Company Pty Ltd. (“PHC”) expired, and the proposed transaction was terminated. Our target acquisition was unable to complete the required financing within the timelines of our agreement, which timelines were extended by more than 45 days to May 17, 2021. Although the proposed transaction with PHC was not completed, the Company is not disregarding the possibility of re-visiting the target acquisition if the impediments are resolved.

Up until two weeks ago, COVID-19 restrictions in Italy prohibited us from accessing our harvest from last year’s growing season. Once the restrictions were lifted by the Italian authorities, we immediately re-sampled our current stock and are now awaiting laboratory results from the testing.

Currently, in our inventory, we have the following hemp stock:

12,685 kg of biomass, no fiber

6,720 kg of biomass with fiber

878 kg of flowers

As liquid yields from biomass and flowers will differ, and the price of our products in the markets fluctuate, management will report on the income received from our stock once sales are finalized. The Company’s objective is to joint venture the processing or refining of our harvest for sale in the market, a process which we expect to be completed within the next 60 – 90 days.

“We thank our shareholders for their patience in what has been a very trying year and look forward to coming out of the global pandemic with renewed vigor and positive results for all,” concluded Robert Eadie, President and CEO of HFH.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and

licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

See Item 2.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

8. Describe the acquisition of new customers or loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Company's President & CEO advanced the sum of \$130,000 to the Company to repay outstanding payables. The advance is deemed to be an interest-free unsecured loan, ranking ahead of any other Company indebtedness.

14. Provide details of any securities issued and options or warrants granted.

No shares were issued from treasury in the month of May 2021. No new options or warrants were granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
N/A			

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

See item 13 in the foregoing.

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 4, 2021.

Gary Arca
Name of Director or Senior Officer

(sgd.) "Gary Arca"
Signature

CFO
Official Capacity

<i>Issuer Details</i>		For Month End	Date of Report
Name of Issuer HEMP FOR HEALTH INC.		May 2021	June 4, 2021
Issuer Address Suite 750, 580 Hornby Street			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Vancouver, BC V6C 3B6	(604) 602-4936	(604) 602-4935	
Contact Name	Contact Position	Contact Telephone No.	
Gary Arca	CFO	(604) 602-4935	
Contact Email Address gary@hempforhealth.eu	Web Site Address www.hempforhealth.eu		